Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human recombinant interleukin-2 as an experimental therapeutic.

× No keyword cloud information.

13 in total

Review 1. Will complex carbohydrate ligands of vascular selectins be the next generation of non-steroidal anti-inflammatory drugs?

Authors: J L Winkelhake
Journal: Glycoconj J Date: 1991-10 Impact factor: 2.916

2. Biological activity of interleukin-2 bound to Candida albicans.

Authors: C B Treseler; R T Maziarz; S M Levitz
Journal: Infect Immun Date: 1992-01 Impact factor: 3.441

Review 3. CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors: Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal: Clin Pharmacokinet Date: 2010-05 Impact factor: 6.447

4. The effect of pH and temperature on the self-association of recombinant human interleukin-2 as studied by equilibrium sedimentation.

Authors: S J Advant; E H Braswell; C V Kumar; D S Kalonia
Journal: Pharm Res Date: 1995-05 Impact factor: 4.200

5. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy.

Authors: J C Becker; N Varki; S D Gillies; K Furukawa; R A Reisfeld
Journal: J Clin Invest Date: 1996-12-15 Impact factor: 14.808

6. Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Authors: J J Bergers; W Den Otter; H F Dullens; C T Kerkvliet; D J Crommelin
Journal: Pharm Res Date: 1993-12 Impact factor: 4.200

Review 7. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors: Ruth Whittington; Diana Faulds
Journal: Drugs Date: 1993-09 Impact factor: 9.546

8. Persistent augmentation of natural-killer- and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose.

Authors: P A Palmer; J G Scharenberg; B M von Blomberg; A G Stam; C J Meijer; G J Roest; C R Franks; R J Scheper
Journal: Cancer Immunol Immunother Date: 1994-07 Impact factor: 6.968

9. Local anaesthetic-like effect of interleukin-2 on muscular Na+ channels: no evidence for involvement of the IL-2 receptor.

Authors: A Kaspar; H Brinkmeier; R Rüdel
Journal: Pflugers Arch Date: 1994-01 Impact factor: 3.657

10. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.

Authors: Y F Zhai; W J Esselman; C S Oakley; C C Chang; C W Welsch
Journal: Cancer Immunol Immunother Date: 1992 Impact factor: 6.968